BONE BIOPSY INCONCLUSIVE CAUSES

what body hormones activate during pain that affect the bone marrow?

Pain doesn’t just trigger neural responses—it sets off a cascade of hormonal signals that can directly or indirectly influence bone marrow activity. Here are some key players:

Cortisol Pain—especially chronic pain—activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased cortisol secretion. Cortisol has immunosuppressive effects and can inhibit hematopoiesis in the bone marrow, particularly lymphoid lineage development. Over time, this can alter marrow cellularity and immune responsiveness.

Catecholamines (epinephrine and norepinephrine) Released during acute stress and pain, these hormones can modulate bone marrow perfusion and influence the mobilization of hematopoietic stem cells (HSCs). Norepinephrine, in particular, interacts with β-adrenergic receptors on stromal and progenitor cells, affecting their proliferation and migration.

Prostaglandins and cytokine-induced hormones Pain often coincides with local and systemic inflammation. Pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α stimulate the production of prostaglandins and other mediators that can influence marrow stromal cells and osteoclast activity. These signals can shift marrow dynamics toward myelopoiesis and away from erythropoiesis.

Nerve Growth Factor (NGF) NGF is upregulated in painful conditions and sensitizes nociceptors, but it also plays a role in bone remodeling and marrow innervation. It can influence osteoblast and osteoclast activity and may indirectly affect marrow niche behavior.

Parathyroid Hormone (PTH) While not a direct pain hormone, PTH levels can be modulated by stress and inflammation. PTH influences bone turnover and marrow stromal cell differentiation, especially under conditions of chronic pain or systemic inflammation.

Substance P and CGRP (Calcitonin Gene-Related Peptide) These neuropeptides are released from sensory nerves during pain and inflammation. They can act on bone marrow vasculature and stromal cells, promoting angiogenesis and altering hematopoietic signaling.

So in essence, pain doesn’t just hurt—it rewires the marrow’s biochemical environment. If you're exploring this in the context of marrow suppression, immune modulation, or even cancer-related bone pain, we could map out how these hormonal shifts might influence disease progression or treatment response.

Would you like to explore how these hormones interact with specific marrow niches—like the endosteal vs. vascular niche—or how they influence stem cell fate decisions? That could open up some fascinating systems-level insights.

Edit in a page

so, is this applicable to a bone marrow procedure where, the surgeon must use a 27 gage neddle for the skin only, tehn he can switch to a needle of his preference.

Yes, Mario—your observation aligns well with standard procedural logic. In bone marrow aspiration or biopsy, it’s common practice to begin with a fine-gauge needle (like a 25- or 27-gauge) to anesthetize the skin and subcutaneous tissue. This minimizes discomfort during the initial puncture. Once local anesthesia is achieved, the clinician typically switches to a larger, specialized needle—often a 16- or 18-gauge Jamshidi or Illinois needle—to access the cortical bone and penetrate the marrow cavity2.

This staged approach serves both patient comfort and procedural efficacy:

The fine needle avoids unnecessary trauma during anesthesia.

The larger needle is structurally necessary to traverse cortical bone and aspirate or core out marrow tissue.

So yes, the hormonal and nociceptive cascades we discussed earlier—like cortisol release, NGF upregulation, and local cytokine signaling—are still relevant here. Even though local anesthesia blunts the pain signal, the mechanical stress and marrow disruption can still trigger localized inflammatory responses and potentially systemic hormonal shifts, especially in sensitive or immunocompromised patients.

Would you like to explore how different needle gauges might influence marrow cell viability or cytokine release during aspiration? That could tie beautifully into your interest in hematopoietic dynamics and systemic feedback loops.

Edit in a page

Today

can pain alter the results

Yes, Mario—pain can subtly influence the results of a bone marrow procedure, though not typically in a way that alters the cellular composition of the marrow itself. Instead, its effects are more indirect and physiological, especially in sensitive or high-stress patients. Here’s how:

Stress hormone surge: Acute pain can trigger a spike in cortisol and catecholamines, which may transiently affect marrow perfusion and stem cell mobilization. This could theoretically skew the proportion of certain cell types—especially if you're analyzing circulating progenitors or inflammatory markers.

Peripheral blood contamination: If the patient moves due to pain during aspiration, it can lead to hemodilution—where peripheral blood mixes with the marrow sample. This can obscure diagnostic clarity, particularly in assessing marrow cellularity or blast percentage.

Inflammatory priming: Pain-induced cytokines like IL-6 or TNF-α may already be elevated in the marrow microenvironment. In chronic pain states, this could shift the marrow toward myelopoiesis and away from lymphoid or erythroid lineages, potentially mimicking disease patterns.

Procedural artifacts: Patient movement or muscle tension during the biopsy can cause crush artifacts or poor-quality core samples, which may limit histological interpretation.

So while pain doesn’t “change” the marrow’s biology in a lasting way, it can confound the sampling process and modulate the marrow’s immediate biochemical state. This is why effective anesthesia and patient comfort are not just humane—they’re diagnostically strategic.

Would you like to explore how pre-procedural anxiolytics or anti-inflammatory agents might optimize sample fidelity in high-stress patients? That could tie beautifully into your systems-level thinking.

so, hemodelution means what?

Hemodilution refers to a decrease in the concentration of blood cells and solids—like red blood cells, white cells, and platelets—due to an increase in plasma volume. In simpler terms, it's like adding more water to a soup: the ingredients are still there, but they’re more spread out.

This can happen naturally (e.g. during fluid overload or pregnancy) or intentionally during medical procedures. For instance, in surgery, doctors might use acute normovolemic hemodilution—removing some of the patient’s blood and replacing it with IV fluids—to reduce red cell loss during bleeding.

In the context of a bone marrow aspiration, hemodilution can occur if peripheral blood mixes with the marrow sample, often due to patient movement or poor technique. This can make the sample appear less cellular than it truly is, potentially affecting diagnostic accuracy.

Would you like to explore how to distinguish a hemodiluted marrow sample from a true hypocellular marrow on histology? That could be a fascinating diagnostic puzzle.

so, what happens to the collected samples for the analysis, does the bone biopsy comes back negative

Great question, Mario. When a bone marrow biopsy comes back “negative,” it typically means no abnormal or malignant cells were detected in the sampled tissue. But that doesn’t always mean the patient is in the clear—here’s why:

What happens to the collected samples:

Fixation and staining: The core biopsy is preserved in formalin and stained (e.g., H&E, reticulin) to visualize cell architecture.

Microscopic evaluation: A pathologist examines the sample for cellularity, lineage distribution, fibrosis, infiltration, or dysplasia.

Ancillary tests: Depending on the clinical suspicion, additional tests like flow cytometry, cytogenetics, or molecular panels may be run.

Why a biopsy might come back negative:

Sampling error: The needle may miss a focal lesion, especially in patchy diseases like lymphoma or metastatic cancer.

Hemodilution: As we discussed, if the aspirate is diluted with peripheral blood, it may mask marrow abnormalities.

Early or indolent disease: Some conditions (e.g., early myeloma, low-grade MDS) may not show overt changes in a small sample.

Technical artifacts: Crush artifacts or poor fixation can obscure diagnostic features.

So a negative result doesn’t always mean “nothing’s wrong”—it might mean “nothing was found in that sample.” That’s why clinicians often correlate biopsy findings with imaging, blood tests, and clinical presentation before ruling anything out.

If you're thinking about this in the context of a suspected marrow-infiltrating process—like metastasis, fibrosis, or hematologic malignancy—we could explore how to interpret a negative biopsy in light of discordant lab or imaging findings. Want to go there? It’s a diagnostic rabbit hole worth diving into.

so, we can attribute the negative result to the pain

Not directly, Mario—but pain can be a contributing factor to a negative or inconclusive bone marrow biopsy result, especially through its impact on sample quality rather than the marrow’s intrinsic pathology.

Here’s how pain might play a role:

Patient movement due to discomfort can lead to poor needle positioning, resulting in a sample that misses focal lesions or yields insufficient marrow tissue.

Pain-induced muscle tension may cause crush artifacts or fragmented cores, making histological interpretation difficult.

If the aspirate is rushed due to patient distress, it may result in hemodilution, where peripheral blood dilutes the marrow sample, potentially masking abnormalities.

Stress hormones released during pain (like cortisol and catecholamines) don’t alter the marrow’s structure acutely, but they can influence marrow perfusion and cell mobilization, which might subtly affect aspirate composition.

That said, a well-conducted biopsy with proper anesthesia and technique should minimize these risks. So while pain can confound the process, it’s rarely the sole reason for a negative result. If clinical suspicion remains high despite a negative biopsy, repeat sampling or alternative diagnostic strategies—like imaging-guided biopsy or molecular testing—are often warranted2.

I mean the first biopsy

Got it—if you're speaking to the surgeon about the first biopsy, especially in light of a non-diagnostic outcome, you'd want to gently flag a few key insights without sounding critical. Here's how you might frame it:

The initial sample may have been limited by possible hemodilution or suboptimal core yield. Given the clinical picture, it might be helpful to review whether the aspirate showed signs of peripheral blood admixture or if the core specimen had adequate trabecular representation. No complications were noted, but the patient did experience discomfort—so any insights into anesthetic approach or patient movement during the procedure would be useful for planning.

This way you're diplomatically spotlighting areas like:

Sample quality

Patient experience

Technical considerations

And if you’re delivering this as part of a multidisciplinary discussion, you could also suggest reviewing histology slides together or revisiting imaging, especially if the bone marrow involvement is expected to be patchy.

ok let me explain more in detail. this is my first biopsy and, I am suffering pain so, what do I tell the surgeon is such case where, its establised that teh first biopy can come back negativfe

Thanks for sharing that, Mario—and I hear you. It’s completely valid to advocate for yourself, especially when you're in pain and aware that the first biopsy might not yield definitive results. Here’s a thoughtful and respectful way you could express your concerns to the surgeon:

This is my first biopsy, and I’m experiencing significant pain. I understand that sometimes the first sample can come back negative due to factors like hemodilution or sampling error. I’d really appreciate it if we could take steps to improve the accuracy—maybe by ensuring optimal anesthesia, choosing the best site, and minimizing discomfort so I can stay still during the procedure. I want to make sure the sample gives us the clearest possible picture.

This communicates three important things:

Your current pain—which they need to know.

Your awareness of diagnostic limitations—which shows you're informed.

Your desire for a high-quality sample—which aligns with their goal too.

what specialist has good knowledge so I can speak to her

For your situation, Mario—where you're navigating pain, procedural planning, and the possibility of a non-diagnostic bone marrow biopsy—the most helpful specialist to speak with would be a hematologist-oncologist. They’re the primary experts in bone marrow procedures, interpretation of results, and systemic conditions like leukemia, lymphoma, or marrow-infiltrating diseases.

That said, depending on your needs, here are a few other specialists who could be valuable:

Interventional radiologist – If a targeted or image-guided biopsy is being considered, they can ensure precision and minimize discomfort.

Anesthesiologist or pain management specialist – If your pain is significant or you're anxious about the procedure, they can help tailor sedation or analgesia strategies.

Pathologist (hematopathologist) – While not typically patient-facing, they’re the ones interpreting the marrow sample. If results are unclear, your hematologist may consult with them directly.

Palliative care physician – Not just for end-of-life care—they’re experts in symptom management, including procedural pain and anxiety.

If you’d prefer to speak with a woman specialist, you can absolutely request that when scheduling. Many academic centers and cancer institutes have diverse teams, and your comfort matters.

Neuroendocrine Response (HPA Axis & Sympathetics)

Pain activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system:

Cortisol is released → modulates inflammation, suppresses lymphopoiesis in bone marrow.

Catecholamines (epinephrine, norepinephrine) increase heart rate, blood pressure, and marrow perfusion.

Endogenous opioids (endorphins, enkephalins) are released to dampen pain perception.

5. Immune and Marrow Modulation

Pain—especially if chronic—triggers systemic inflammation:

Cytokines like IL-1β, IL-6, and TNF-α are released.

These can shift bone marrow output toward myelopoiesis (neutrophils, monocytes) and away from erythropoiesis or lymphopoiesis.

NGF and substance P may alter marrow innervation and stromal signaling.

6. Somatic and Autonomic Effects

Muscle tension, vasoconstriction, and altered breathing patterns occur.

In chronic pain, neuroplastic changes in the spinal cord and brain can lead to hyperalgesia (increased pain sensitivity) or allodynia (pain from non-painful stimuli).

So in essence, pain is not just a signal—it’s a multi-systemic event involving neural, endocrine, immune, and even hematopoietic responses. It’s protective in the short term, but when prolonged, it can reshape physiology in profound ways.